Copyright
©The Author(s) 2016.
World J Gastroenterol. Apr 14, 2016; 22(14): 3803-3812
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3803
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3803
Table 1 Baseline characteristics of all patients
Characteristic | Met the Milan criteria (n = 109) | Did not meet the Milan criteria (n = 59) | ||||
Low-dose HBIG | High-dose HBIG | P value | Low-dose HBIG | High-dose HBIG | P value | |
(n = 62) | (n = 47) | (n = 33) | (n = 26) | |||
Age (yr) | 53.8 ± 6.4 | 53.6 ± 7.6 | 0.854 | 54.1 ± 7.4 | 53.0 ± 8.7 | 0.608 |
Sex (male/female) | 49/13 | 35/12 | 0.575 | 30/3 | 21/5 | 0.284 |
Child-Pugh score | 7 (5-13) | 5 (5-12) | 0.002 | 7 (5-13) | 6 (5-13) | 0.226 |
AFP (ng/mL) | 18.8 (2.0-8891.8) | 13.3 (1.8-3811.2) | 0.407 | 30.7 (3.5-31142.9) | 235.3 (2.9-57348.8) | 0.049 |
Number of tumors | 1 (1-3) | 1 (1-3) | 0.857 | 1 (1-8) | 1 (1-5) | 0.743 |
Largest tumor size (cm) | 2.2 (0.6-4.5) | 2.2 (0.8-4.0) | 0.504 | 5.4 (0.9-13.0) | 4.9 (1.1-25.0) | 0.976 |
Edmond-Steiner grade (I,II/III,IV) | 26/36 | 21/26 | 0.774 | 8/25 | 2/24 | 0.161 |
Major vessel invasion (absent/present) | 62/0 | 47/0 | N/A | 26/7 | 17/9 | 0.250 |
Microvascular invasion (absent/present) | 42/17[3] | 30/17 | 0.420 | 11/22 | 6/20 | 0.388 |
Bile duct invasion (absent/present) | 61/1 | 42/2 | 0.577 | 31/2 | 23/3 | 0.646 |
Satellite nodule (absent/present) | 46/15[1] | 37/10 | 0.686 | 14/19 | 11/15 | 0.993 |
Table 2 Baseline characteristics of propensity-matched patients with low- and high-dose Hepatitis B Immunoglobulin who met and did not meet the Milan criteria
Characteristic | Met the Milan criteria (38 pairs) | Did not meet the Milan criteria (18 pairs) | ||||
Low-dose HBIG | High-dose HBIG | P value | Low-dose HBIG | High-dose HBIG | P value | |
(n = 38) | (n = 38) | (n = 18) | (n = 18) | |||
Age (yr) | 52.7 ± 5.5 | 53.4 ± 8.1 | 0.643 | 52.9 ± 8.0 | 53.3 ± 8.6 | 0.917 |
Sex (male/female) | 32/6 | 29/9 | 0.453 | 16/2 | 16/2 | 1.000 |
Child-Pugh score | 6 (5-12) | 6 (5-12) | 0.710 | 6 (5-13) | 6 (5-13) | 0.932 |
AFP (ng/mL) | 22.6 (2.0-8891.8) | 15.3 (1.8-3811.2) | 0.658 | 34.6 (3.5-31142.9) | 112.5 (2.9-57348.8) | 0.500 |
Number of tumors | 1 (1-3) | 1 (1-3) | 0.963 | 1 (1-5) | 1 (1-5) | 0.811 |
Largest tumor size (cm) | 2.2 (0.8-4.5) | 2.1 (0.8-4.0) | 0.994 | 5.75 (1.6-13.0) | 4.9 (1.1-25.0) | 0.393 |
Edmond-Steiner grade (I, II/III, IV) | 17/21 | 17/21 | 1.000 | 4/14 | 2/16 | 0.500 |
Major vessel invasion (absent/present) | 38/0 | 38/0 | N/A | 12/6 | 13/5 | 1.000 |
Microvascular invasion (absent/present) | 23/15 | 26/12 | 0.664 | 5/13 | 4/14 | 1.000 |
Bile duct invasion (absent/present) | 37/1 | 37/1 | 1.000 | 16/2 | 16/2 | 1.000 |
Satellite nodule (absent/present) | 26/12 | 29/9 | 0.648 | 6/12 | 5/13 | 1.000 |
- Citation: Lee EC, Kim SH, Lee SD, Park H, Lee SA, Park SJ. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol 2016; 22(14): 3803-3812
- URL: https://www.wjgnet.com/1007-9327/full/v22/i14/3803.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i14.3803